What Is a Research-Chemical Vendor Allowed to Say?

A research-chemical vendor can say what the material is, meaning its identity, sequence, purity, quantity, analytical results and storage conditions, and nothing that presents it as having an effect in a person. In the United States, the United Kingdom and Australia, regulators decide what a product is by looking at everything said and shown around it, and a statement that something is for research only does not cancel a claim made elsewhere on the same page 136.

The site already has a page on where the phrase research use only came from and what it commits a supplier to. This one is about the claims test that governs everything else a vendor says: how each regulator reads a product page, why such pages look so sparse, and why careful wording is never enough on its own. It describes how regulators reason. It is not legal or compliance advice.

What is the claims test?

It is the question of what a product is being presented as for, answered from the evidence rather than from the seller's stated intention. Each of the three systems asks it differently, but all three reach the same place: a product put forward as treating, preventing or changing something in a person is treated as a medicine, and then the whole of medicines law applies 137.

The test is deliberately broad. If classification depended only on what a label said, anyone could escape medicines law by printing a different sentence. So the regulators look past the label to the whole presentation, and the label becomes one piece of evidence among many.

How does the FDA decide what a product is for?

By objective intent, shown by the seller's own expressions and conduct. The regulation defining intended use says it may be shown by labelling claims, advertising matter, or oral or written statements by the seller or its representatives, and by the circumstances surrounding distribution, including where an article is offered or used, with the seller's knowledge, for a purpose for which it is neither labelled nor advertised 1.

The FDA has applied that directly to peptide sellers. In a December 2024 warning letter to one research-peptide company, the agency wrote that despite labelling marketing its products as "RESEARCH USE ONLY" and "INTENDED AS A RESEARCH CHEMICAL ONLY," evidence from its websites established that the products were intended to be drugs for use in people. It treated them as unapproved new drugs under the Federal Food, Drug, and Cosmetic Act, citing website and social media material that promoted the products for metabolic conditions 2.

The lesson of that letter is not about any single phrase. It is that the FDA read the whole business, websites and social media together, and found the research designation contradicted by the rest of what the company said.

How does the MHRA approach it in the UK?

Through the definition of a medicinal product, which catches anything presented as having properties for treating or preventing disease in people, together with strict controls on how medicines may be advertised. Both sit in the Human Medicines Regulations 2012, and the MHRA's advertising guidance, the Blue Guide, explains how it applies the advertising provisions 34.

In 2026 the MHRA stated its position on research labels without ambiguity. It said that peptide products may fall under the cosmetics, supplements or medicines frameworks depending on their intended purpose, and that it disregards claims that products are for "research purposes" if it is clear those claims are being used as an attempt to avoid medicines regulations 5. That remark was made in the context of its inquiry into clinics, but the principle is general.

What about Australia?

Australia adds an advertising prohibition that does not depend on the claims test at all for scheduled substances. Prescription and pharmacist-only medicines, meaning products containing substances in the prescription and pharmacist schedules, are generally prohibited from being advertised to the public, and the TGA's guidance states that a disclaimer or caveat does not exempt material from that restriction 6.

That makes Australia the strictest of the three on promotion. In the other two systems the question is whether a page presents a product as a medicine; in Australia, for a substance already scheduled, promoting it to the public can be the problem in itself.

Why do research product pages read the way they do?

Because every element that would normally sell a product is also potential evidence of intended use, so a page written for the research channel strips them out. What remains is a description of the material as a chemical: its name and synonyms, its sequence, its molecular formula and weight, its stated purity, the analytical method behind that figure, the batch, the storage conditions and the research designation.

The omissions are more telling than the contents. A page written to that standard has no benefits, no testimonials, no images of people or bodies, no comparisons of appearance over time, no instructions for giving the material to anyone, no suggested amounts, no language borrowed from clinics, and no curated selection of studies arranged to imply an effect. Each of those, under the tests above, is the sort of thing a regulator reads as presentation.

• Typically stated: identity, sequence, formula, molecular weight, purity and the method used, batch or lot, quantity, form, storage conditions, the research designation.
• Typically absent: benefits, testimonials and reviews about effects, pictures of people, instructions for administration, amounts for administration, treatment language, condition names framed as uses.

Does a clean product page make a vendor compliant?

No, because regulators do not read the product page in isolation. The United States standard expressly takes in oral and written statements by representatives and the circumstances of distribution, and the FDA's December 2024 letter drew on social media as well as websites 12. Affiliate content, influencer posts, customer-service replies, packaging inserts and the kind of customer a business visibly serves can all become part of the presentation.

This is also why the sparse page is a floor rather than a strategy. A business can have a page that says nothing about people and still be treated as selling medicines if everything around the page says otherwise. The MHRA's remark about disregarding research labels used to avoid regulation describes exactly that situation 5.

Can a vendor refer to published research on a compound?

It can describe what a compound is and where it appears in the scientific literature, but a selection of studies arranged to suggest an effect in people is read as a claim. The distinction is the same one that runs through every test above: regulators look at the impression a presentation creates, not at whether each individual sentence is literally true 13.

A neutral description of a compound's structure, its history and the kinds of models in which it has been studied is information about a chemical. A page that gathers findings under headings about recovery, appearance or metabolism, quotes the most favourable results and leaves out the limits is doing what an advertisement does, with footnotes. The footnotes do not change what the page is presenting, and nor does the fact that the underlying papers are real.

Does compliant wording make a sale lawful?

No. Wording decides only one question, whether a product is being presented as a medicine. It does not decide whether a substance is scheduled, whether it may be imported, whether it may be possessed, or whether any other law applies.

Australia shows this most clearly. A substance scheduled as prescription-only is controlled whatever the page says, and the restriction on advertising prescription medicines to the public is not lifted by a caveat 6. In the European system, from which the UK definition descends, a product can be a medicine by function as well as by presentation, so silence about effects does not settle classification either 7. A page that makes no claims is necessary for the research channel to exist at all. It is never sufficient to make a transaction lawful.

So what is a research-chemical vendor allowed to say?

Facts about the material, and nothing that presents it as acting on a person, on any channel the business controls. That is the common core of three quite different systems 136.

Read in that light, a sparse product page is not coyness or a legal trick. It reflects the fact that the research channel is defined by an absence of claims, and that the absence has to hold across the whole business, not just in the small print. Where it does not hold, the regulators in all three countries have said, in their own words and in their own enforcement, that the label will not save it.